Cannabics Pharmaceuticals Announced the Launch of WanaCaps XR in Colorado

BETHESDA, MD--(Marketwired - Jun 22, 2015) - Cannabics Pharmaceuticals Inc. (OTC PINK: CNBX) is proud to announce that its strategic partner Wana Products has this week formally launched "WannaCaps xr," a series of extended release cannabis capsules that provide beneficial effects for up to multiple hours per dose.

Cannabics Pharmaceuticals Inc., a U.S. based Bio Tech Development Company with R&D in Israel, developed the unique proprietary technology behind the extended release formulation and licenses this technology to Wana. Cannabics chose Wana over all other licensed Colorado Medicinal Edible manufacturers due to their high quality control standards and professionalism in their business ethics.

WanaCaps_xr will be offered in three different formulations: capsules with a 10:1 CBD to THC ratio (WanaCaps_xr High CBD Capsules), a 10:1 THC to CBD ratio (WanaCaps_xr High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCaps_xr THC/CBD Balanced Capsules). Each package of WanaCaps_xr contains ten 10 mg capsules, allowing for precise dosing based on the patient's individual needs and tolerance.

"The extended release formulation enables patients to dose once or twice daily so they can get on with their lives without the constant need to be thinking about re-dosing," said Nancy Whiteman, co-owner of Wana Products. "Additionally the new capsules also address one of the major concerns of cannabis patients, which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness," Whiteman added. "Instead, with WanaCaps_xr, patients experience a long-lasting, stable effect without the ups and downs."

"Cannabics researchers are making breakthroughs in the medical evolution of cannabis, and WanaCaps_xr is on the leading edge of those advancements," said Dr. Eyal Ballan, Chief Scientist of Cannabics Pharmaceuticals. "Wana's new XR product will help legal medical marijuana states approach the roll out of medical cannabis in a new, controlled, stable and effective way."

Because all of Cannabics Pharmaceuticals R&D is in Israel, we can progress further and faster than possible right now in the US. In fact, within the Ministry of Health, there is a stand-alone division -- the "Israeli Medical Cannabis Agency" (IMCA). In October 2014, IMCA through the Israeli Ministry of Health granted Cannabics Pharmaceuticals an exclusive government license to research in the field of cannabinoid science.

Cannabics Pharmaceuticals is now undertaking a comprehensive clinical trial in partnership with the Oncology Department of Rambam Hospital in Haifa, Israel. Further, Cannabics Pharmaceuticals is currently in a collaborative research project with the Technion Institute on cannabinoids and cancer cell biology.

Cannabics Pharmaceuticals exclusively licenses its patented IP technology to Wanna for its production of the capsules. The innovative venture between Wana Products and Cannabics Pharmaceuticals offers an amazing window into the nexus between Biotechnology and the need for a more scientific standardized approach in states where such products are now legal.

About Wana Products
Wana Products, based in Boulder, leads Colorado's edibles and medical marijuana industry in quality and consistency. Since 2010, Wana Products has made marijuana infused products including a full line of edibles, and now WanaCaps_xr, a series of extended release cannabis capsules. For more information, visit http://www.wanacaps.com. Become a fan of Wana Products on Facebook. Follow Wana Products on Instagram.

About Cannabics Pharmaceuticals, Inc.
CANNABICS PHARMACEUTICALS, INC. (CNBX) is a US public company with Research & Development conducted in its laboratories in Israel. The company is dedicated to the development of advanced and sophisticated cannabinoid-based treatments and therapies. The Company's main focus is development of various novel therapies and biotechnological tools aimed relating to diverse ailments and treating human malignancies. These advanced tools include novel delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds and bioinformatics tools. Cannabics Pharmaceuticals Inc. is strictly a bio-tech research company which develops its proprietary technologies in GMP certified laboratories and licenses the use of these IP technologies. Cannabics Pharmaceuticals Inc. does not manufacture, distribute, or dispense any controlled substances, including cannabis or cannabis-based preparations.

DISCLAIMER:
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 20^th, 2015. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.